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Aim To investigate the association between plasma con-
centrations of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) and formation of esophageal varices.
Methods Thirty-five patients with alcoholic cirrhosis were 
divided into three groups according to the Child-Pugh 
classification: grade A (n = 11, 32%), B (n = 12, 34%), and 
C (n = 12, 34%). System hemodynamic parameters were 
measured using sphygmomanometry, electrocardiogra-
phy, and echocardiography. NT-proBNP was analyzed by 
using an electrochemiluminiscence sandwich immunoas-
say.
Results The presence of esophageal varices was associ-
ated with a higher serum NT-proBNP level, with a cut-off 
value of >101 pg/mL (sensitivity, 87.60% and specificity, 
72.73%; P < 0.001).
Conclusions NT-proBNP was found to be a marker of the 
presence of esophageal varices, but not a marker of pro-
gression of liver cirrhosis. In cirrhotic patients, NT-proBNP 
value >101 pg/mL was shown to be a valuable noninva-
sive parameter in predicting the presence of varices.
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Cirrhotic patients are characterized by hyperdynamic circu-
lation with increased cardiac output, heart rate and plasma 
volume, normal or low arterial blood pressure, and decreased 
systemic vascular resistance (1-3). The pathophysiology of 
this syndrome consists of interactions between system he-
modynamic and neurohumoral parameters (4-9).
Pro-B-type natriuretic peptide (proBNP1-108) is a 108-ami-
no acid prohormone secreted from the cardiomyocytes 
secondary to cardiac wall distension and stretching, and 
neurohumoral activation in response to ventricular volume 
and pressure overload (10). The presence of brain natriuret-
ic peptide (BNP) may be regarded as counter-regulatory 
to the actions of the sympathetic and renin-angiotensin-
aldosterone systems (RAAS). Natriuretic peptide secretion 
leads to natriuresis, vasodilation activation with a concomi-
tant inhibition of the renin-angiotensin-aldosterone system 
and adrenergic activity, inhibition of cardiomyocyte hyper-
trophy, angiogenesis promotion, and delay in the activa-
tion of cardiac fibroblasts, all of which results in improved 
myocardial relaxation (11,12). Patients with cirrhosis had el-
evated levels of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), without signs of reduced hepatic degradation 
of this hormone, and elevated plasma levels of BNP in these 
patients correlated best with diastolic dysfunction (4,13-16). 
However, there was no significant relation of NT-proBNP lev-
els to other measures of hyperdynamic circulation, such as 
cardiac output or systemic vascular resistance (15). A study 
that evaluated the severity of disease compared to plasma 
levels of BNP in non-alcoholic cirrhotic patients found no 
significant BNP level difference between patients with and 
without esophageal varices (17). The role of NT-proBNP in 
the formation of esophageal varices and the relationship 
between proBNP plasma concentration and presence of 
varices has not been established.
The aim of this study is to investigate the association be-
tween plasma concentrations of NT-proBNP and formation 
of esophageal varices. Additionally, we investigated the as-
sociation between plasma concentrations of NT-proBNP 
and severity of liver disease (Child-Pugh score), presence 
of ascites, as well as hemodynamic and neurohumoral pa-
rameters involved in modified circulatory homeostasis in 
patients with alcoholic liver cirrhosis.
PATieNTs AND MeThoDs
Patients
The study included 35 adult male and female patients di-
agnosed with alcoholic liver cirrhosis from urban and sub-
urban parts of Zadarska County in Croatia treated in the 
General Hospital Zadar. Age range of eligible patients was 
32-83 years. The diagnosis of liver cirrhosis included a com-
plex set of typical clinical findings including relevant medi-
cal history, presenting symptoms, decreased prothrombin 
time, hypoalbuminemia with albumin-globulin inversion, 
hypergammaglobulinemia, advanced diffuse chronic he-
patic lesion on abdominal ultrasound examination, or liver 
biopsy (9 patients).
Patients with liver cirrhosis of other etiology than alcohol 
and patients with suspected malignant comorbidity, ad-
vanced multiorgan disorders or infections, acute gastroin-
testinal bleeding, cardiac arrhythmias, ischemic or valvular 
heart disease, renal failure, along with those treated with 
pharmacological agents that potentially affect systemic 
circulation, such as beta-adrenergic blockers or nitrates 
were not included in the study. Patients treated with di-
uretics were included.
All patients signed an informed consent prior to the inclu-
sion according to the approval of the ethics committee of 
General Hospital Zadar and following good clinical prac-
tice criteria.
study design
The patients were asked to fast overnight and then lie 
down for approximately two hours prior to having blood 
samples taken and system hemodynamic parameters mea-
sured. The blood samples were used to measure liver func-
tion tests, plasma renin activity, and NT-proBNP concentra-
tions. System hemodynamic parameters were measured 
by using a sphygmomanometer, electrocardiography, and 
echocardiography. System circulation assessment included 
heart and great vessels within the mediastinum and was 
done by the Philips ATL Ultramark 7 (National Ultrasound, 
Duluth, GA, USA) ultrasound device by combining pulse 
Doppler and two-dimensional echocardiography of the left 
ventricle in lying supine patients.
system hemodynamic parameters
We measured the serum levels of NT-proBNP, noradrena-
lin (NRA), and plasma rennin activity (PRA), and cardiac in-
dex (CI), systemic vascular resistance (SVR), stroke volume 
(SV), cardiac output (CO), and mean arterial blood pres-
sure (MAP). Arterial blood pressure was measured with a 
sphygmomanometer. Mean arterial blood pressure was 
calculated as the sum of one-third of the systolic plus 
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2-fold diastolic values (MAP = 1 (systolic)/3 + 2 (diastolic)/3). 
The ratio of cardiac output to body surface represented the 
cardiac index (CI = CO/body surface). Systemic vascular resis-
tance index (SVRI) was calculated by multiplication of MAP 
and 80, divided by cardiac index (SVRI = MAP × 80/CI).
Sample volume values were measured just above the aor-
tal valve with pulsating Doppler. Aortal valve diameter val-
ues were obtained from parasternal longitudinal position 
and aortic valve surface area was calculated by the formu-
la r2π. Stroke volume was calculated by multiplying valve 
surface area with the integral of valve flow velocity. Car-
diac minute output volume represented multiplication of 
stroke volume with pulse rate recorded through synchro-
nized electrocardiography.
Laboratory analysis
Propeptide of the brain natriuretic peptide was analyzed in 
plasma by using an electrochemiluminiscence sandwich 
immunoassay (Elecsys proBNP, Roche Diagnostics, Meylan, 
France) (18). Plasma rennin activity was measured by using 
a commercial RIA kit (Alpco Diagnostics, Salem, NH, USA).
statistical analyses
According to Smirnov-Kolmogorov test, appropriate para-
metric tests were used in the analyses: independent t test, 
ANOVA, and Pearson correlation. Receiver operating char-
acteristic (ROC) curve analysis was used to define cut-off 
value of proBNP regarding varices. P values less than 0.05 
were considered significant. IBM SPSS, version 19.0.0.1 
(SPSS Inc., Chicago, IL, USA) and MedCalc for Windows, ver-
sion 11.5 (www.medcalc.be) were used.
ResuLTs
This study included 35 patients with an age range from 
32 to 83 years (median value, 62). Patients were divided 
into three groups according to the Child-Pugh classifica-
tion: grade A (n = 11, 32%), B (n = 12, 34%), and C (n = 12, 
34%). Esophageal varices were found in 24 (69%) patients, 
whereas ascites was found in 21 (60%) patients.
Mean value ± standard deviation of CI was 3.6 ± 1.0 L/min/
m2, of SVR 2187.6 ± 625.9 dyn · s/cm5, of SV 85.3 ± 19.6 mL, 
of CO 7.1 ± 2.0 L/min, and of MAP 92.1 ± 8.1 mm Hg.
There was no significant association of NT-proBNP, 
NRA, and PRA with CI, SVR, and SV in neither of the 
groups. A significant association was found between NRA 
and SV and between NRA and CO (P = 0.053) in the group A 
(P = 0.006). In the group B, there was a negative association 
between NRA and MAP (P = 0.071). Patients without esopha-
geal varices had a significant association between NRA and 
SV (P = 0.006), and between NT-proBNP and MAP (P = 0.021).
Patients with esophageal varices (n = 24, 69%) had a signifi-
cantly higher serum NT-proBNP level (median value 338.63 
pg/mL [range 69.17-6052.5] vs 47.72 [range 11.31-570.42]; 
P = 0.014) than patients without esophageal varices. Addi-
tional analysis showed the serum level of NT-proBNP>101 
pg/mL as a cut-off value for the presence of esophageal 
varices in patients with liver cirrhosis (P < 0.001), with a sen-
sitivity of 87.60% and specificity of 72.73% (Figure 1).
Patients with liver cirrhosis also had significantly lower val-
ues of MAP (89 vs 97 mm Hg) (P = 0.001). There were no 
significant differences in NRA, PRA, CI, SVR, SV, and CO 
values between the groups of patients with and without 
esophageal varices. Patients with ascites (n = 21, 60%) had 
significantly lower MAP values (89 vs 96 mm Hg; P = 0.010) 
(Table 1).
TABLe 1. Average values of neurohumoral and system hemo-
dynamic parameters
esophageal varices 
(mean ± standard deviation)
Characteristic present (n = 24) not present (n = 11) P†
proBNP (pg/mL) 1628.25 ± 1019.82  166.30 ± 127.20 0.014
NRA  827.43 ± 176.37    3.17 ± 1.49 0.316
PRA   11.56 ± 6.67    7.09 ± 5.49 0.714
CI    3.57 ± 1.09    3.73 ± 0.81 0.625
SVR 2197.14 ± 719.12 2166.85 ± 376.92 0.871
SV   82.00 ± 19.88   92.65 ± 17.79 0.128
CO    6.97 ± 2.13    7.44 ± 1.78 0.501
MAP   89.58 ± 8.03   97.75 ± 5.37 0.001
Ascites
present (n = 21) not present (n = 14)
proBNP(pg/mL) 1700.70 ± 998.99  672.31 ± 348.73 0.127
NRA  884.50 ± 200.75    3.70 ± 2.09 0.319
PRA    7.36 ± 12.23    4.71 ± 6.43 0.409
CI    3.61 ± 1.08    3.63 ± 0.92 0.950
SVR 2146.57 ± 642.10 2249.20 ± 619.28 0.640
SV   82.43 ± 19.54   89.72 ± 19.67 0.291
CO    7.11 ± 2.10    7.13 ± 1.95 0.976
MAP   89.60 ± 9.23   95.97 ± 4.21 0.010
*Abbreviations: NRA – noradrenalin; PRA – plasma renin activity; Ci – 
cardiac index; sVR – systemic vascular resistance; sV – stroke volume; 
Co – cardiac output; MAP – mean arterial pressure.
†independent t test.
377Ljubičić et al: NT-proBNP as a noninvasive marker of esophageal varices
www.cmj.hr
DisCussioN
Our study showed an association between NT-proBNP and 
cardiac dysfunction, but the association with the progres-
sion of the disease was not established. With increasing 
disease stage, plasma NT-proBNP levels were greater and 
SV was lower. This correlates with the hyperdinamic cir-
culation theory based on a central hypovolemia (17) and 
systolic dysfunction (19). Among system hemodynamic 
parameters, MAP was shown as a possible marker of dis-
ease progression, with a decrease in its level observed in 
advanced stages of liver disease, and a positive associa-
tion with NT-proBNP and negative association with NRA. In 
advanced cirrhosis with pronounced vasodilatation, cen-
tral hypovolemia and arterial hypotension, RAAS and sym-
pathic system are highly activated causing hyperdinamic 
circulation. Low MAP is a result of reduced vascular reactiv-
ity to adrenaline and angiotensin-II because of increased 
release of nitric oxide (20).
Patients with cirrhosis and ascites present with lower 
blood pressure, lower peripheral vascular resistance, and 
increased stroke volume (21). The association between NT-
proBNP and ascites is currently deemed controversial. Woo 
et al did not find differences in plasma NT-proBNP level 
between pre-ascitic and ascitic patients (19). However, Yi-
lidizz et al found higher plasma NT-proBNP level in ascitic 
patients (17). Our study did not find any difference in plas-
ma NT-proBNP level between patients with and without 
ascites. In our opinion, these results can be explained by 
high sodium intake and concomitant use of diuretic thera-
py, which lower BNP concentration (22).
It has been demonstrated that patients without esopha-
geal varices have a lower cardiac index and systolic volume, 
higher values of peripheral vascular resistance, and mean 
arterial blood pressure (23). In cirrhotic patients, portal hy-
pertension evolves due to increased portal venous resis-
tance together with increased blood flow within the por-
tal venous system. Both are the consequence of splanchnic 
arterial vasodilation caused by endotoxemia, through the 
opening of portosystemic collaterals, which leads to re-
duced activity of RAAS and intestinal disturbance resulting 
in increased synthesis of vasodilatators. As cirrhosis pro-
gresses, effective hypovolemia and arterial hypotension 
progress and RAAS induces low renal perfusion, glomerular 
filtration rate, and subsequently sodium and water reten-
tion, which together aggravate systolic and diastolic dys-
function, leading to increased production of NT-proBNP. 
NT-proBNP as a contraregulatory mechanism for decreas-
ing portal hypertension induces natriuresis, vasodilation 
activation with a concomitant inhibition of the renin-an-
giotensin-aldosterone system and adrenergic activity. In 
our study, higher variceal grade was accompanied by lower 
levels of MAP and higher NT-proBNP plasma levels, which 
confirms the presented theory. We found that the cut-off 
of NT-proBNP serum level >101 pg/mL was a marker of 
esophageal varices. This could be useful as a clinical param-
eter and diagnostic tool for detecting esophageal varices in 
cirrhotic patients. However, a major limitation of our study 
is the small number of patients and further larger prospec-
tive studies are needed to confirm our results and establish 
the eventual use of this parameter in clinical practice. The 
small number of patients and concomitant use of diuret-
ics could also be reasons why no association between NT-
proBNP levels and stage of disease progression was found. 
Therefore, we can conclude that NT-proBNP could be con-
sidered as a marker of presence of varices in liver cirrhosis, 
but not as a marker of disease progression.
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